Vascular Inflammation Screening for Future Cardiac Events

Abstract

Vascular inflammation is a critical yet underrecognized contributor to the pathogenesis of atherosclerosis and subsequent cardiac events. Emerging evidence suggests that screening for vascular inflammation may improve risk stratification and guide targeted interventions to mitigate cardiovascular morbidity and mortality. This review synthesizes current scientific literature, outlines the mechanistic underpinnings of vascular inflammation, evaluates established and novel screening modalities, and discusses clinical implications for the early identification and management of patients at heightened risk for future cardiac events.

Introduction

Cardiovascular disease (CVD) remains the leading cause of morbidity and mortality worldwide, despite significant advances in prevention and therapy. While traditional risk factors such as hypertension, hyperlipidemia, diabetes, and smoking are well-established, the role of vascular inflammation as a pivotal driver of atherothrombotic events is gaining recognition. Inflammation not only initiates but also propagates vascular injury, contributing to plaque instability and acute coronary syndromes. Recognizing its importance, there is growing interest in developing robust screening strategies to detect vascular inflammation and predict future cardiac events more accurately.

Epidemiology / Disease Burden

The global burden of CVD is profound, accounting for nearly 18 million deaths annually. Epidemiological studies indicate that a substantial proportion of cardiac events occur in individuals without overt risk factors, highlighting the limitations of conventional risk assessment tools. Inflammatory biomarkers such as high-sensitivity C-reactive protein (hs-CRP) have shown independent prognostic value, with elevated levels correlating with increased incidence of myocardial infarction and stroke. Population-based cohorts, such as the JUPITER trial, have underscored the predictive utility of inflammation markers in primary prevention settings, reinforcing the need for systematic screening approaches.

Pathophysiology

Vascular inflammation is orchestrated by complex interactions between endothelial cells, leukocytes, and circulating cytokines. Endothelial dysfunction, triggered by oxidative stress, hyperglycemia, and dyslipidemia, facilitates the recruitment of monocytes and T-lymphocytes to the vascular intima. These infiltrating cells release pro-inflammatory mediators such as interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), and monocyte chemoattractant protein-1 (MCP-1) which amplify local inflammation and promote the formation of vulnerable plaques. These plaques, characterized by thin fibrous caps and rich lipid cores, are prone to rupture, precipitating acute coronary syndromes.

Risk Factors

Traditional CVD risk factors age, male sex, hypertension, diabetes, and dyslipidemia are intimately linked to vascular inflammation. Additionally, chronic inflammatory conditions such as rheumatoid arthritis, systemic lupus erythematosus, and psoriasis have been associated with increased cardiovascular risk, independent of conventional factors. Lifestyle elements, including smoking, obesity, physical inactivity, and dietary patterns, modulate systemic inflammatory load, further influencing vascular health. Genetic predispositions, such as single nucleotide polymorphisms in inflammatory genes, may also modulate individual susceptibility to vascular inflammation.

Clinical Features

Vascular inflammation is typically subclinical, with overt manifestations often arising only after the development of advanced atherosclerotic disease. Patients may present with angina pectoris, transient ischemic attacks, or peripheral arterial insufficiency in later stages. However, asymptomatic individuals with heightened inflammatory activity remain at risk for acute cardiac events, underscoring the importance of proactive screening and risk assessment in clinical practice.

Diagnosis

Current diagnostic modalities for vascular inflammation encompass circulating biomarkers, imaging techniques, and molecular assays. High-sensitivity CRP remains the most widely used biomarker, with IL-6, fibrinogen, and lipoprotein-associated phospholipase A2 (Lp-PLA2) providing additional prognostic information. Advanced imaging modalities such as positron emission tomography (PET) with fluorodeoxyglucose (FDG), coronary computed tomography angiography (CCTA), and magnetic resonance imaging (MRI) with specific contrast agents allow for the direct visualization of inflamed vascular segments and plaque characterization. Integration of multi-modality approaches is increasingly advocated for refined risk stratification.

Treatment & Management

The management of patients with evidence of vascular inflammation necessitates a multifaceted approach. Aggressive modification of traditional risk factors via statin therapy, antihypertensive agents, glycemic control, and lifestyle interventions remains foundational. Statins, beyond their lipid-lowering effects, exert potent anti-inflammatory actions, reducing CRP and other inflammatory markers. Adjunctive therapies, such as colchicine and monoclonal antibodies targeting IL-1β (e.g., canakinumab), have demonstrated benefit in selected populations, heralding a paradigm shift in the treatment of residual inflammatory risk.

Recent Advances / Emerging Therapies

Recent years have witnessed the emergence of novel therapeutics aimed at modulating vascular inflammation. The CANTOS trial provided compelling evidence that IL-1β inhibition reduces recurrent cardiovascular events independently of lipid lowering. Similarly, low-dose colchicine, as shown in the COLCOT and LoDoCo2 trials, significantly reduced composite cardiovascular outcomes in patients with stable coronary disease. Investigational agents targeting other pathways such as IL-6 inhibition and NLRP3 inflammasome modulation are currently under evaluation. Advances in molecular imaging and circulating cell-free RNA profiling may further enhance the detection and monitoring of vascular inflammation.

Guideline Recommendations

Major cardiovascular societies increasingly acknowledge the role of inflammation in atherosclerosis. The 2019 ACC/AHA guidelines recommend consideration of hs-CRP measurement to refine risk assessment in select patients. European guidelines endorse the integration of inflammatory markers and advanced imaging for high-risk individuals. However, routine screening for vascular inflammation in the general population is not currently advocated, pending further evidence on clinical utility and cost-effectiveness. Personalized approaches, targeting high-risk patients with persistent inflammatory activity despite optimal therapy, are recommended.

Conclusion

Screening for vascular inflammation represents a promising frontier in cardiovascular risk stratification and prevention. While significant progress has been made in elucidating the mechanisms and clinical relevance of vascular inflammation, further research is needed to define optimal screening strategies and therapeutic targets. Integration of biomarker assays, advanced imaging, and individualized management protocols may ultimately improve outcomes for patients at risk for future cardiac events. Ongoing clinical trials and guideline updates will refine best practices, ensuring that advances in vascular inflammation screening translate into meaningful reductions in cardiovascular morbidity and mortality.